IMPORTANT DISCLAIMER: Blank Capital Research ("BCR") is a technology platform, not a registered investment advisor or broker-dealer. The algorithmically generated signals, scores, and rankings provided on this site ("God Mode" Signals) are for informational and research purposes only and do not constitute financial advice, investment recommendations, or an offer to sell or solicit an offer to buy any securities.
HYPOTHETICAL PERFORMANCE RESULTS: The "timing scores" and "regime signals" displayed are based on quantitative models. Hypothetical or simulated performance results have certain inherent limitations. Unlike an actual performance record, simulated results do not represent actual trading. Also, since the trades have not actually been executed, the results may have under-or-over compensated for the impact, if any, of certain market factors, such as lack of liquidity.
RISK OF LOSS: Trading in financial markets involves a high degree of risk and may result in the loss of your entire investment. Data provided by third-party sources (Intrinio, Snowflake) is believed to be reliable but is not guaranteed for accuracy or completeness. Past performance is not indicative of future results.
Relative valuation derived from Healthcare sector median benchmarks. Model weights: EV/EBITDA (40%), P/B (35%), P/S (25%). Multiples adjusted for extreme outliers and non-recurring volatility.
Auditing capital efficiency...
Quality Profile Audit
Score: 37.1GRADE D
Composite assessment of profitability, capital efficiency, and financial strength. Top-tier entities demonstrate sustainable cash flow generation.
Return on Equity
Profit generated per dollar of shareholder equity
18.9%
Sector: -43.5%
Dividend Analysis audit
No Dividend
This company does not currently pay a dividend.
Analyst Projections
Analyst Consensus
Unlock Valuation Tools
Sign up for free access to institutional-quality research tools.
Based on our 6-factor quantitative model, ALCON INC (ALC) receives a "Hold" rating with a composite score of 48.0/100, ranked #1716 out of 4446 stocks. Key factor scores: Quality 37/100, Value 68/100, Momentum 44/100. This is quantitative analysis only — not investment advice.
ALCON INC (ALC) Stock Analysis — April 2026 Rating, Price, and Forecast
Company Overview — What Does ALCON INC Do?
Alcon Inc., an eye care company, researches, develops, manufactures, distributes, and sells eye care products for eye care professionals and their patients worldwide. The company's Surgical segment offers equipment, instrumentation and diagnostics, intraocular lenses (IOLs), and other implantables; and consumables, including viscoelastics, surgical solutions, incisional instruments, surgical custom packs, and other products for use in surgical procedures. Its cataract products include centurion vision system, LenSx femtosecond laser, LuxOR surgical ophthalmic microscope, NGENUITY 3D visualization system, and ORA system for intra-operative measurements; custom pak surgical procedure packs; vitreoretinal products comprising constellation vision systems, procedure packs, lasers and hand-held microsurgical instruments, and grieshaber and MIVS instruments, as well as scissors, forceps and micro-instruments, medical grade vitreous tamponades, and Hypervit vitrectomy probes; refractive surgery products, including WaveLight lasers and Contoura Vision used for LASIK treatment; EX-PRESS glaucoma filtration device; and implantables products, including AcrySof IQ IOLs products include monofocal IOLs and advanced technology IOLs under the PanOptix and ReSTOR brands for the correction of presbyopia and astigmatism at the time of cataract surgery. Its Vision Care segment provides daily disposable, reusable, and color-enhancing contact lenses; ocular health products, such as dry eye, glaucoma, contact lens care, and ocular allergies; and ocular vitamins and redness relievers under the TOTAL, PRECISION, DAILIES AquaComfort PLUS, Air Optix, Opti-Free, Clear Care, Tears Naturale, Genteal, ICAPS, and Vitalux brands. The company was formerly known as Alcon Universal S.A. and changed the name to Alcon Inc. in December 2001. Alcon Inc. was founded in 1945 and is headquartered in Geneva, Switzerland. ALCON INC (ALC) is classified as a large-cap stock in the Healthcare sector, specifically within the Medical Equipment industry. The company is led by CEO David J. Endicott and employs approximately 25,200 people. With a market capitalization of $36.8B, ALC is one of the prominent companies in the Healthcare sector.
ALCON INC (ALC) Stock Rating — Hold (April 2026)
As of April 2026, ALCON INC receives a Hold rating with a composite score of 48.0/100 and 3 out of 5 stars from the Blank Capital Research quantitative model.ALC ranks #1,716 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, ALCON INC ranks #170 of 838 stocks, placing it in the top quartile of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).
ALC Stock Price and 52-Week Range
ALCON INC (ALC) currently trades at $78.01. The stock gained $0.61 (0.8%) in the most recent trading session. The 52-week high for ALC is $99.20, which means the stock is currently trading -21.4% from its annual peak. The 52-week low is $71.55, putting the stock 9.0% above its annual trough. Recent trading volume was 1.5M shares, reflecting moderate market activity.
Is ALC Overvalued or Undervalued? — Valuation Analysis
ALCON INC (ALC) carries a value factor score of 68/100 in the Blank Capital model, indicating fair valuation relative to historical norms. The trailing price-to-earnings ratio is 37.57x, compared to the Healthcare sector average of 23.63x — a premium of 59%. The price-to-book ratio stands at 1.69x, versus the sector average of 2.75x. The price-to-sales ratio is 0.92x, compared to 1.66x for the average Healthcare stock. On an enterprise value basis, ALC trades at 3.77x EV/EBITDA, versus 6.34x for the sector. The EV/EBIT multiple is 33.10x.
Overall, ALC's valuation appears roughly in line with sector benchmarks, suggesting the market is pricing the stock fairly given its current fundamentals and growth trajectory. Neither deep value nor significantly overpriced, the stock occupies a middle ground on valuation.
ALCON INC Profitability — ROE, Margins, and Quality Score
ALCON INC (ALC) earns a quality factor score of 37/100, signaling below-average profitability metrics relative to the broader market. The return on equity (ROE) is 18.9%, compared to the Healthcare sector average of -43.5%, which is within a healthy range. Return on assets (ROA) comes in at 13.4% versus the sector average of -33.1%.
On a margin basis, ALCON INC reports gross margins of 55.6%, compared to 71.5% for the sector. The operating margin is 13.5% (sector: -66.1%). Net profit margin stands at 10.3%, versus -58.7% for the average Healthcare stock. Revenue growth is running at 6.6% on a trailing basis, compared to 10.6% for the sector. Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.
ALC Debt, Balance Sheet, and Financial Health
ALCON INC has a debt-to-equity ratio of 24.0%, compared to the Healthcare sector average of 32.0%. The low leverage indicates a conservative balance sheet with significant financial flexibility. Total debt on the balance sheet is $5.07B. Cash and equivalents stand at $1.68B.
ALC has a beta of 0.84, meaning it is roughly in line with the broader market in terms of price volatility. The stability factor score for ALCON INC is 78/100, indicating low-volatility characteristics and consistent price behavior that appeals to risk-averse investors.
ALCON INC Revenue and Earnings History — Quarterly Trend
In TTM 2026, ALCON INC reported revenue of $9.91B and earnings per share (EPS) of $2.06. Net income for the quarter was $1.02B. Gross margin was 55.6%. Operating income came in at $1.34B.
In FY 2024, ALCON INC reported revenue of $9.91B and earnings per share (EPS) of $2.06. Net income for the quarter was $1.02B. Gross margin was 55.6%. Revenue grew 4.8% year-over-year compared to FY 2023. Operating income came in at $1.34B.
In FY 2023, ALCON INC reported revenue of $9.46B and earnings per share (EPS) of $1.98. Net income for the quarter was $974M. Gross margin was 55.5%. Revenue grew 8.5% year-over-year compared to FY 2022. Operating income came in at $959M.
In FY 2022, ALCON INC reported revenue of $8.72B and earnings per share (EPS) of $0.68. Net income for the quarter was $335M. Gross margin was 54.5%. Revenue grew 5.1% year-over-year compared to FY 2021. Operating income came in at $636M.
Over the past 8 quarters, ALCON INC has demonstrated a growth trajectory, with revenue expanding from $7.15B to $9.91B. Investors analyzing ALC stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.
ALC Dividend Yield and Income Analysis
ALCON INC (ALC) does not currently pay a dividend. This is common among growth-oriented companies in the Medical Equipment industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.
ALC Momentum and Technical Analysis Profile
ALCON INC (ALC) has a momentum factor score of 44/100, reflecting neutral trend characteristics. The stock is neither significantly outperforming nor underperforming the broader market on a momentum basis. The investment factor score is 57/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 20/100 signals elevated short interest, which can indicate bearish sentiment among institutional investors.
ALC vs Competitors — Healthcare Sector Ranking and Peer Comparison
Comparing ALC against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full ALC vs S&P 500 (SPY) comparison to assess how ALCON INC stacks up against the broader market across all factor dimensions.
ALC Next Earnings Date
No upcoming earnings date has been announced for ALCON INC (ALC) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.
Should You Buy ALC? — Investment Thesis Summary
ALCON INC presents a balanced picture with arguments on both sides. The quality score of 37/100 flags below-average profitability. The value score of 68/100 suggests attractive pricing relative to fundamentals. Low volatility (stability score 78/100) reduces downside risk.
In summary, ALCON INC (ALC) earns a Hold rating with a composite score of 48.0/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on ALC stock.
We'll email you when stocks you follow change their composite rating.
Institutional Research Dossier
ALCON INC (ALC) Deep Dive Analysis
Published on March 24, 2026
Action RatingHold
Sections
Executive Summary
We maintain our Hold rating on Alcon (ALC). While Alcon operates in a structurally attractive market with favorable demographic trends and has demonstrated consistent revenue growth, its current valuation appears to fully reflect these positives. The company's profitability metrics, while improving, still lag sector leaders, and its relatively high debt levels introduce a degree of financial risk that warrants caution.
Alcon's strategic focus on innovation and expansion in both surgical and vision care segments is encouraging, but the competitive landscape remains intense, and the company's ability to consistently generate free cash flow is crucial for sustaining its growth trajectory and managing its debt obligations. The current valuation leaves little margin for error, making a Hold rating appropriate until we see further evidence of sustained margin expansion and stronger free cash flow generation.
Business Strategy & Overview
Alcon operates through two primary segments: Surgical and Vision Care. The Surgical segment focuses on products used in cataract, refractive, and vitreoretinal surgery, including equipment, intraocular lenses (IOLs), and consumables. This segment benefits from an aging global population and increasing demand for vision correction procedures. Alcon's strategy involves continuous innovation in IOL technology, surgical equipment, and visualization systems to enhance surgical outcomes and efficiency. The Vision Care segment offers a range of contact lenses (daily disposable, reusable, and color-enhancing) and ocular health products, addressing needs from dry eye to glaucoma. This segment's strategy centers on expanding its product portfolio with innovative lens materials and designs, as well as developing solutions for managing various eye conditions.
Alcon's strategic positioning is built on its established brand reputation, extensive distribution network, and strong relationships with eye care professionals. The company invests heavily in research and development to maintain a competitive edge in both segments. Its product pipeline includes next-generation IOLs, advanced surgical platforms, and novel contact lens technologies. A key aspect of Alcon's strategy is to expand its presence in emerging markets, where demand for eye care products and services is growing rapidly. This involves tailoring product offerings to local needs and building partnerships with local distributors and healthcare providers.
The industry context is characterized by increasing competition from both established players and emerging companies. Technological advancements are driving innovation in surgical procedures and contact lens materials. Regulatory requirements and pricing pressures also pose challenges. Alcon's ability to navigate these challenges and capitalize on growth opportunities will be critical to its long-term success. The company's focus on innovation, geographic expansion, and strategic partnerships is designed to address these challenges and drive sustainable growth.
Alcon's business model relies on a combination of product sales and recurring revenue from consumables and services. The Surgical segment generates revenue from the sale of equipment and IOLs, as well as from the ongoing sale of consumables used in surgical procedures. The Vision Care segment generates revenue from the sale of contact lenses and ocular health products, with a significant portion of revenue coming from repeat purchases of contact lenses. The company's ability to maintain strong relationships with eye care professionals is crucial for driving sales and ensuring customer loyalty.
Execution Benchmarks audit
Revenue Growth
YOY expansion rate
6.6%
Sector: 10.6%
-38% VS SCTR
Economic Moat Analysis
Alcon possesses a narrow economic moat, primarily derived from intangible assets and switching costs. The company's established brand reputation and strong relationships with eye care professionals create a degree of customer loyalty and preference for its products. This is particularly evident in the Surgical segment, where surgeons often prefer to use familiar equipment and IOLs. The Vision Care segment also benefits from brand recognition and customer loyalty, especially for established brands like TOTAL and DAILIES AquaComfort PLUS.
Switching costs also contribute to Alcon's moat, particularly in the Surgical segment. Surgeons invest significant time and effort in learning to use specific surgical equipment and techniques. Switching to a different system requires retraining and adaptation, which can be costly and time-consuming. This creates a barrier to entry for competitors and provides Alcon with a degree of pricing power. However, the moat is not wide because competitors also have established relationships and innovative products, and the switching costs are not insurmountable.
While Alcon benefits from intangible assets and switching costs, it does not possess a significant cost advantage or benefit from efficient scale. The company's gross margins are lower than the sector average, suggesting that it does not have a significant cost advantage over its competitors. The medical device industry is also characterized by relatively low barriers to entry for new competitors, which limits Alcon's ability to achieve efficient scale. The company's moat is therefore considered narrow, providing it with a competitive advantage but not a dominant position in the market.
The strength of Alcon's moat is also influenced by the pace of innovation in the eye care industry. Rapid technological advancements can erode the competitive advantages of established players, as new products and technologies emerge. Alcon's ability to continuously innovate and adapt to changing market conditions is crucial for maintaining its moat. The company's investments in research and development are therefore critical for sustaining its competitive advantage over the long term.
Financial Health & Profitability
Alcon's financial health has shown improvement in recent years, with consistent revenue growth and increasing profitability. Revenue has grown from $6.83 billion in FY2020 to $9.91 billion in FY2024, representing a compound annual growth rate (CAGR) of approximately 9.7%. This growth has been driven by strong performance in both the Surgical and Vision Care segments. Net income has also improved significantly, from a loss of $531 million in FY2020 to a profit of $1.02 billion in FY2024. This improvement reflects the company's efforts to improve operational efficiency and reduce costs.
However, Alcon's profitability metrics still lag the sector average. Its gross margin of 55.6% is lower than the sector average of 71.9%, and its operating margin of 13.5% is also lower than the sector average of -65.2% (although the sector average is skewed by outliers). This suggests that Alcon has room to improve its profitability by increasing its gross margins and reducing its operating expenses. The company's return on equity (ROE) of 18.9% is significantly better than the sector average of -42.5%, indicating that it is generating a higher return on its equity investments.
Alcon's balance sheet is characterized by a moderate level of debt. The company's total debt of $5.07 billion is higher than its total cash of $1.68 billion, resulting in a net debt position. The company's debt-to-equity ratio of 24.00 is lower than the sector average of 30.00, suggesting that it is not excessively leveraged. However, the company's ability to generate free cash flow is crucial for managing its debt obligations. Free cash flow has improved significantly in recent years, from negative levels in FY2020-FY2022 to $942.84 million in FY2024. This improvement reflects the company's increasing profitability and improved working capital management.
The historical trend in free cash flow is concerning. While FY2023 and FY2024 show positive FCF, the preceding years were deeply negative. This raises questions about the sustainability of the recent FCF improvements. A consistent track record of positive FCF generation is essential for Alcon to fund its growth initiatives, manage its debt, and return capital to shareholders. The company's ability to maintain and improve its free cash flow generation will be a key factor in its long-term financial health.
Valuation Assessment
Alcon's valuation appears to be fair, based on its current financial performance and growth prospects. The company's price-to-earnings (P/E) ratio of 35.8x is higher than the sector average of 24.3x, suggesting that it is trading at a premium to its peers. However, this premium may be justified by the company's strong revenue growth and improving profitability. The company's EV/EBITDA ratio of 3.7x is lower than the sector average of 6.4x, indicating that it may be undervalued on an enterprise value basis.
The company's free cash flow yield, calculated as free cash flow divided by market capitalization, is approximately 2.6%. This is a relatively low yield, suggesting that the company is not generating a significant amount of free cash flow relative to its market value. However, the company's free cash flow is expected to grow in the coming years, which could lead to an increase in its free cash flow yield. The current valuation appears to reflect expectations of continued growth and margin expansion.
Compared to its historical valuation, Alcon's current P/E ratio is higher than its historical average, reflecting the improvement in its profitability. However, its EV/EBITDA ratio is lower than its historical average, suggesting that it may be undervalued on an enterprise value basis. The company's valuation is also influenced by its growth prospects. Alcon is expected to continue to grow its revenue and earnings at a healthy rate in the coming years, driven by strong demand for its products and services. This growth potential justifies a higher valuation than companies with lower growth prospects.
Overall, Alcon's valuation appears to be fair, reflecting its strong revenue growth, improving profitability, and growth prospects. However, the company's relatively low free cash flow yield and high debt levels introduce a degree of risk that warrants caution. The current valuation leaves little margin for error, making a Hold rating appropriate until we see further evidence of sustained margin expansion and stronger free cash flow generation. Any significant deviation from expected growth rates or profitability could negatively impact the company's valuation.
Risk & Uncertainty
Alcon faces several risks and uncertainties that could impact its financial performance and valuation. One of the primary risks is competition. The eye care industry is highly competitive, with numerous established players and emerging companies vying for market share. Alcon faces competition from companies such as Johnson & Johnson, Bausch Health, and Carl Zeiss Meditec. Intense competition could lead to pricing pressures, reduced market share, and lower profitability.
Another risk is regulatory uncertainty. The medical device industry is subject to strict regulatory requirements, and changes in regulations could impact Alcon's ability to market and sell its products. For example, changes in reimbursement policies or approval processes could delay or prevent the launch of new products. Alcon is also subject to product liability claims, which could result in significant financial losses. The company's ability to comply with regulatory requirements and manage product liability risks is crucial for its long-term success.
A further risk is related to product innovation and obsolescence. The eye care industry is characterized by rapid technological advancements, and Alcon must continuously innovate to maintain its competitive edge. Failure to develop and launch new products could lead to a loss of market share and reduced profitability. The company's investments in research and development are therefore critical for mitigating this risk. Furthermore, Alcon's reliance on key suppliers and distributors could also pose a risk. Disruptions in the supply chain or the loss of key distribution agreements could negatively impact its ability to manufacture and sell its products.
Finally, Alcon's relatively high debt levels introduce a degree of financial risk. The company's ability to generate free cash flow is crucial for managing its debt obligations. A decline in profitability or an increase in interest rates could make it more difficult for Alcon to service its debt, potentially leading to financial distress. The company's management of its debt levels and its ability to generate free cash flow will be key factors in mitigating this risk.
Bulls Say / Bears Say
The Bull Case
BULL VIEWAlcon's strong brand recognition and established relationships with eye care professionals provide a significant competitive advantage, allowing it to maintain market share and pricing power.
BULL VIEWThe aging global population and increasing prevalence of vision disorders will drive strong demand for Alcon's products and services, leading to sustained revenue growth and improved profitability.
BULL VIEWAlcon's focus on innovation and expansion in emerging markets will unlock new growth opportunities and further strengthen its competitive position.
The Bear Case
BEAR VIEWAlcon's relatively high debt levels and low free cash flow yield make it vulnerable to economic downturns and rising interest rates, potentially limiting its ability to invest in growth initiatives.
BEAR VIEWIntense competition in the eye care industry could lead to pricing pressures and reduced market share, eroding Alcon's profitability and undermining its competitive advantage.
BEAR VIEWRegulatory uncertainty and product liability risks could result in significant financial losses and damage Alcon's reputation, negatively impacting its valuation.
About the Author
Marques Blank
Founder & Chief Investment Officer, Blank Capital
Marques brings 15 years of institutional finance and investing experience, having overseen financial planning for a $1.6B defense business unit. He developed the proprietary 6-factor quantitative model used to score ALC and 4,400+ other equities.
ALCON INC exhibits a 16% valuation discount relative to institutional benchmarks. This represents a constructive entry window based on current multiples.
Return on Assets
Efficiency of asset utilization
13.4%
Sector: -33.1%
Gross Margin
Pricing power and cost efficiency
55.6%
Sector: 71.5%
Operating Margin
Core business profitability
13.5%
Sector: -66.1%
Net Margin
Bottom-line profitability
10.3%
Sector: -58.7%
Factor Methodology
The Quality factor evaluates the persistence and magnitude of cash flows. Companies with scores >70 exhibit superior competitive moats and financial resilience through economic cycles.
